PMID- 25952996
OWN - NLM
STAT- MEDLINE
DCOM- 20160323
LR  - 20171206
IS  - 1724-6040 (Electronic)
IS  - 0391-3988 (Linking)
VI  - 38
IP  - 5
DP  - 2015 May
TI  - Therapeutic potential of umbilical cord mesenchymal stem cells in mice with acute 
      hepatic failure.
PG  - 271-6
LID - 10.5301/ijao.5000390 [doi]
AB  - BACKROUND/OBJECTIVE: Mesenchymal stem cells are probably one of the most 
      promising alternatives for liver regeneration and repair. We present data 
      supporting the ability of human umbilical cord mesenchymal stem cells (hUCMSCs) 
      to generate hepatic elements and discuss the best transplantation pathway. 
      METHODS: AHF mice were given hUCMSCs through tail-vein injection or into the 
      liver lobes. Blood serum and liver tissues were collected to analyze the 
      improvement of liver function and histological repair 24 h after hUCMSC 
      administration. Real-time polymerase chain reaction and immunohistochemistry were 
      used to detect the expression of human hepatocyte-specific markers in liver 
      tissues. RESULTS: The results showed significant statistical differences in liver 
      function after transplantation (P<.05). Real-time PCR and immunochemistry 
      results demonstrated that the expression of hepatocyte-specific markers such as 
      CK18 and AFP were obviously increased in the treatment groups through both 
      transplantation pathways. Our data indicate that hUCMSCs are one of the stem cell 
      candidates for liver repair because hUCMSCs can be easily and readily isolated 
      and differentiated into hepatocytes both in vitro and in vivo. Additionally, 
      tail-vein injection of hUCMSCs has a similar therapeutic efficacy but is more 
      convenient compared to liver lobe injection. CONCLUSIONS: Our findings highlight 
      the potential therapeutic value of hUCMSCs and show that cell transplantation 
      through a peripheral vein is a safe and effective way to treat AHF mice. 
      Furthermore, this method might mediate repair in patients with liver damage or 
      disease in future clinical therapy.
FAU - Feng, Ting
AU  - Feng T
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Chongqing 
      Medical University, Chongqing Key Laboratory of Infectious Diseases and Parasitic 
      Diseases, Chongqing - China.
FAU - Zhang, Jun
AU  - Zhang J
FAU - Zeng, Guifang
AU  - Zeng G
FAU - Zhou, Rong
AU  - Zhou R
FAU - Tang, Xiaohong
AU  - Tang X
FAU - Cui, Chang
AU  - Cui C
FAU - Li, Yongyong
AU  - Li Y
FAU - Wang, Hongwei
AU  - Wang H
FAU - Li, Tao
AU  - Li T
FAU - Zhu, Weimin
AU  - Zhu W
FAU - Yu, Zebo
AU  - Yu Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150429
PL  - United States
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Liver/*pathology
MH  - Liver Failure, Acute/pathology/*therapy
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mice
MH  - Treatment Outcome
MH  - Umbilical Cord/*cytology
EDAT- 2015/05/09 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/05/09 06:00
PHST- 2015/01/18 00:00 [accepted]
PHST- 2015/05/09 06:00 [entrez]
PHST- 2015/05/09 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
AID - 355C9B4E-D6A6-473D-88B5-5FF6FA024F76 [pii]
AID - 10.5301/ijao.5000390 [doi]
PST - ppublish
SO  - Int J Artif Organs. 2015 May;38(5):271-6. doi: 10.5301/ijao.5000390. Epub 2015 
      Apr 29.